Last reviewed · How we verify
NCT07278674: CSHEIN
Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN）
trial testing Oral administration of eflornithine for the prevention of high-risk neuroblastoma in High Risk Neuroblastoma in 20 participants. Participants enrolled and being followed up; not accepting new ones.
31 October 2029
Quick facts
| Lead sponsor | Shanghai Children's Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 8 April 2025 |
| Primary completion | 31 October 2029 |
| Estimated completion | 31 October 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- Oral administration of eflornithine for the prevention of high-risk neuroblastoma — full drug profile →
Conditions studied
- High Risk Neuroblastoma — all drugs for High Risk Neuroblastoma →
Sponsor
Shanghai Children's Hospital
Who can join
Adults 1 Month to 18, any sex, with High Risk Neuroblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate the impact of maintenance therapy with eflornithine on event-free survival and overall survival in high-risk neuroblastoma (NB) children after immunotherapy, and assess its safety.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07278674
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for High Risk Neuroblastoma
Currently open trials in the same condition.
- NCT03794349 — Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed · Phase 2 · active not recruiting
- NCT03786783 — Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastom · Phase 2 · active not recruiting
Other Shanghai Children's Hospital trials
Trials by the same sponsor.
- NCT05476640 — Newborn Sequencing Screening in China · unknown
- NCT05206799 — The CMCPCTH Research in Chinese Children · unknown
- NCT05092425 — Analysis of Risk Factors for Children With Heterochronous Indirect Hernia · unknown
- NCT04937907 — Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) · Phase 2 · completed
- NCT07495176 — USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07278674 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Children's Hospital
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07278674.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing